- Oops!Something went wrong.Please try again later.
Shares of Recro Pharma (NASDAQ:REPH) were flat in pre-market trading after the company reported Q2 results.
Earnings per share decreased 92.31% over the past year to ($0.25), which missed the estimate of ($0.16).
Revenue of $15,522,000 decreased by 50.34% year over year, which missed the estimate of $18,880,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 10, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/3xhm9v2z
52-week high: $19.21
52-week low: $3.99
Price action over last quarter: down 9.22%
Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.